nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Darifenacin—Angioedema—Lisinopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Darifenacin—Confusional state—Mycophenolic acid—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Darifenacin—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Darifenacin—Abdominal pain—Captopril—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Darifenacin—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Darifenacin—Oedema—Mycophenolic acid—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Darifenacin—Dry skin—Prednisone—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Darifenacin—Nausea—Pentoxifylline—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Darifenacin—Infection—Mycophenolic acid—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Darifenacin—Diarrhoea—Mometasone—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Darifenacin—Syncope—Lisinopril—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Darifenacin—Shock—Mycophenolic acid—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Darifenacin—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Darifenacin—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Darifenacin—Palpitations—Lisinopril—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Darifenacin—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Darifenacin—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Darifenacin—Loss of consciousness—Lisinopril—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Darifenacin—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Darifenacin—Cough—Lisinopril—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Darifenacin—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Darifenacin—Visual disturbance—Methotrexate—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Darifenacin—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Darifenacin—Insomnia—Leflunomide—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Darifenacin—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Darifenacin—Arthralgia—Lisinopril—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Darifenacin—Back pain—Mycophenolate mofetil—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Darifenacin—Dyspnoea—Leflunomide—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Darifenacin—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Darifenacin—Dyspepsia—Leflunomide—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Darifenacin—Vomiting—Mometasone—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Darifenacin—Dry mouth—Lisinopril—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Darifenacin—Feeling abnormal—Azathioprine—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Darifenacin—Rash—Mometasone—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Darifenacin—Asthenia—Captopril—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Darifenacin—Dermatitis—Mometasone—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Darifenacin—Confusional state—Lisinopril—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Darifenacin—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Darifenacin—Headache—Mometasone—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Darifenacin—Insomnia—Mycophenolic acid—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Darifenacin—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Darifenacin—Oedema—Lisinopril—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Darifenacin—Pruritus—Captopril—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Darifenacin—Pain—Leflunomide—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Darifenacin—Constipation—Leflunomide—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Darifenacin—Infection—Lisinopril—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Darifenacin—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Darifenacin—Somnolence—Mycophenolic acid—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Darifenacin—Shock—Lisinopril—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Darifenacin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Darifenacin—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Darifenacin—Tachycardia—Lisinopril—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Darifenacin—Abdominal pain—Azathioprine—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Darifenacin—Skin disorder—Lisinopril—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Darifenacin—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Darifenacin—Diarrhoea—Captopril—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Darifenacin—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Darifenacin—Erectile dysfunction—Prednisone—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Darifenacin—Feeling abnormal—Leflunomide—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Darifenacin—Nausea—Mometasone—systemic scleroderma	0.0014	0.0014	CcSEcCtD
Darifenacin—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Darifenacin—Weight increased—Prednisone—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Darifenacin—Pain—Mycophenolic acid—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Darifenacin—Constipation—Mycophenolic acid—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Darifenacin—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Darifenacin—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Darifenacin—Cough—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Darifenacin—Dizziness—Captopril—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Darifenacin—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Darifenacin—Abdominal pain—Leflunomide—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Darifenacin—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Darifenacin—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Darifenacin—Breast disorder—Methotrexate—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Darifenacin—Hypersensitivity—Azathioprine—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Darifenacin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Darifenacin—Insomnia—Lisinopril—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Darifenacin—Vomiting—Captopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Darifenacin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Darifenacin—Dyspnoea—Lisinopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Darifenacin—Rash—Captopril—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Darifenacin—Dermatitis—Captopril—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Darifenacin—Somnolence—Lisinopril—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Darifenacin—Headache—Captopril—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Darifenacin—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Darifenacin—Dyspepsia—Lisinopril—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Darifenacin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Darifenacin—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Darifenacin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Darifenacin—Infection—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Darifenacin—Shock—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Darifenacin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Darifenacin—Hypersensitivity—Leflunomide—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Darifenacin—Pain—Lisinopril—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Darifenacin—Constipation—Lisinopril—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Darifenacin—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Darifenacin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Darifenacin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Darifenacin—Diarrhoea—Azathioprine—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Darifenacin—Nausea—Captopril—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Darifenacin—Asthenia—Leflunomide—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Darifenacin—Hallucination—Prednisone—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Darifenacin—Feeling abnormal—Lisinopril—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Darifenacin—Pruritus—Leflunomide—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Darifenacin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Darifenacin—Dizziness—Azathioprine—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Darifenacin—Erectile dysfunction—Methotrexate—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Darifenacin—Asthenia—Mycophenolic acid—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Darifenacin—Diarrhoea—Leflunomide—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Darifenacin—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Darifenacin—Abdominal pain—Lisinopril—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Darifenacin—Pruritus—Mycophenolic acid—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Darifenacin—Vomiting—Azathioprine—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Darifenacin—Eye disorder—Prednisone—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Darifenacin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Darifenacin—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Darifenacin—Infestation NOS—Methotrexate—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Darifenacin—Infestation—Methotrexate—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Darifenacin—Rash—Azathioprine—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Darifenacin—Dermatitis—Azathioprine—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Darifenacin—Headache—Azathioprine—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Darifenacin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Darifenacin—Dizziness—Leflunomide—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Darifenacin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Darifenacin—Stomatitis—Methotrexate—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Darifenacin—Angiopathy—Prednisone—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Darifenacin—Pain—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Darifenacin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Darifenacin—Sweating—Methotrexate—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Darifenacin—Vomiting—Leflunomide—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Darifenacin—Hypersensitivity—Lisinopril—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Darifenacin—Dizziness—Mycophenolic acid—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Darifenacin—Rash—Leflunomide—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Darifenacin—Dermatitis—Leflunomide—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Darifenacin—Mental disorder—Prednisone—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Darifenacin—Nausea—Azathioprine—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Darifenacin—Headache—Leflunomide—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Darifenacin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Darifenacin—Asthenia—Lisinopril—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Darifenacin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Darifenacin—Pruritus—Lisinopril—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Darifenacin—Vomiting—Mycophenolic acid—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Darifenacin—Rash—Mycophenolic acid—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Darifenacin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Darifenacin—Headache—Mycophenolic acid—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Darifenacin—Pharyngitis—Methotrexate—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Darifenacin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Darifenacin—Nausea—Leflunomide—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Darifenacin—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Darifenacin—Vision blurred—Prednisone—systemic scleroderma	0.001	0.001	CcSEcCtD
Darifenacin—Urethral disorder—Methotrexate—systemic scleroderma	0.001	0.001	CcSEcCtD
Darifenacin—Diarrhoea—Lisinopril—systemic scleroderma	0.001	0.001	CcSEcCtD
Darifenacin—Visual impairment—Methotrexate—systemic scleroderma	0.000986	0.000986	CcSEcCtD
Darifenacin—Angioedema—Prednisone—systemic scleroderma	0.000974	0.000974	CcSEcCtD
Darifenacin—Dizziness—Lisinopril—systemic scleroderma	0.000968	0.000968	CcSEcCtD
Darifenacin—Erythema multiforme—Methotrexate—systemic scleroderma	0.000967	0.000967	CcSEcCtD
Darifenacin—Nausea—Mycophenolic acid—systemic scleroderma	0.000966	0.000966	CcSEcCtD
Darifenacin—Eye disorder—Methotrexate—systemic scleroderma	0.000956	0.000956	CcSEcCtD
Darifenacin—Syncope—Prednisone—systemic scleroderma	0.000956	0.000956	CcSEcCtD
Darifenacin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000945	0.000945	CcSEcCtD
Darifenacin—Loss of consciousness—Prednisone—systemic scleroderma	0.000937	0.000937	CcSEcCtD
Darifenacin—Vomiting—Lisinopril—systemic scleroderma	0.000931	0.000931	CcSEcCtD
Darifenacin—Angiopathy—Methotrexate—systemic scleroderma	0.000928	0.000928	CcSEcCtD
Darifenacin—Rash—Lisinopril—systemic scleroderma	0.000923	0.000923	CcSEcCtD
Darifenacin—Dermatitis—Lisinopril—systemic scleroderma	0.000923	0.000923	CcSEcCtD
Darifenacin—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000922	0.000922	CcSEcCtD
Darifenacin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000921	0.000921	CcSEcCtD
Darifenacin—Hypertension—Prednisone—systemic scleroderma	0.00092	0.00092	CcSEcCtD
Darifenacin—Headache—Lisinopril—systemic scleroderma	0.000917	0.000917	CcSEcCtD
Darifenacin—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000908	0.000908	CcSEcCtD
Darifenacin—Arthralgia—Prednisone—systemic scleroderma	0.000907	0.000907	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000901	0.000901	CcSEcCtD
Darifenacin—Mental disorder—Methotrexate—systemic scleroderma	0.000896	0.000896	CcSEcCtD
Darifenacin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000878	0.000878	CcSEcCtD
Darifenacin—Dysgeusia—Methotrexate—systemic scleroderma	0.000872	0.000872	CcSEcCtD
Darifenacin—Nausea—Lisinopril—systemic scleroderma	0.00087	0.00087	CcSEcCtD
Darifenacin—Oedema—Prednisone—systemic scleroderma	0.00087	0.00087	CcSEcCtD
Darifenacin—Anaphylactic shock—Prednisone—systemic scleroderma	0.00087	0.00087	CcSEcCtD
Darifenacin—Infection—Prednisone—systemic scleroderma	0.000864	0.000864	CcSEcCtD
Darifenacin—Back pain—Methotrexate—systemic scleroderma	0.000862	0.000862	CcSEcCtD
Darifenacin—Shock—Prednisone—systemic scleroderma	0.000856	0.000856	CcSEcCtD
Darifenacin—Nervous system disorder—Prednisone—systemic scleroderma	0.000853	0.000853	CcSEcCtD
Darifenacin—Tachycardia—Prednisone—systemic scleroderma	0.000849	0.000849	CcSEcCtD
Darifenacin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000849	0.000849	CcSEcCtD
Darifenacin—Skin disorder—Prednisone—systemic scleroderma	0.000845	0.000845	CcSEcCtD
Darifenacin—Hyperhidrosis—Prednisone—systemic scleroderma	0.000841	0.000841	CcSEcCtD
Darifenacin—Vision blurred—Methotrexate—systemic scleroderma	0.000839	0.000839	CcSEcCtD
Darifenacin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000816	0.000816	CcSEcCtD
Darifenacin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000809	0.000809	CcSEcCtD
Darifenacin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000808	0.000808	CcSEcCtD
Darifenacin—Headache—Mycophenolate mofetil—systemic scleroderma	0.000804	0.000804	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000792	0.000792	CcSEcCtD
Darifenacin—Insomnia—Prednisone—systemic scleroderma	0.000787	0.000787	CcSEcCtD
Darifenacin—Cough—Methotrexate—systemic scleroderma	0.000777	0.000777	CcSEcCtD
Darifenacin—Dyspepsia—Prednisone—systemic scleroderma	0.000766	0.000766	CcSEcCtD
Darifenacin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000762	0.000762	CcSEcCtD
Darifenacin—Arthralgia—Methotrexate—systemic scleroderma	0.000758	0.000758	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000753	0.000753	CcSEcCtD
Darifenacin—Constipation—Prednisone—systemic scleroderma	0.000744	0.000744	CcSEcCtD
Darifenacin—Confusional state—Methotrexate—systemic scleroderma	0.000733	0.000733	CcSEcCtD
Darifenacin—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000727	0.000727	CcSEcCtD
Darifenacin—Infection—Methotrexate—systemic scleroderma	0.000722	0.000722	CcSEcCtD
Darifenacin—Feeling abnormal—Prednisone—systemic scleroderma	0.000717	0.000717	CcSEcCtD
Darifenacin—Nervous system disorder—Methotrexate—systemic scleroderma	0.000713	0.000713	CcSEcCtD
Darifenacin—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000711	0.000711	CcSEcCtD
Darifenacin—Skin disorder—Methotrexate—systemic scleroderma	0.000706	0.000706	CcSEcCtD
Darifenacin—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000703	0.000703	CcSEcCtD
Darifenacin—Abdominal pain—Prednisone—systemic scleroderma	0.000688	0.000688	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000662	0.000662	CcSEcCtD
Darifenacin—Insomnia—Methotrexate—systemic scleroderma	0.000657	0.000657	CcSEcCtD
Darifenacin—Dyspnoea—Methotrexate—systemic scleroderma	0.000648	0.000648	CcSEcCtD
Darifenacin—Somnolence—Methotrexate—systemic scleroderma	0.000646	0.000646	CcSEcCtD
Darifenacin—Hypersensitivity—Prednisone—systemic scleroderma	0.000641	0.000641	CcSEcCtD
Darifenacin—Dyspepsia—Methotrexate—systemic scleroderma	0.00064	0.00064	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000628	0.000628	CcSEcCtD
Darifenacin—Asthenia—Prednisone—systemic scleroderma	0.000624	0.000624	CcSEcCtD
Darifenacin—Pain—Methotrexate—systemic scleroderma	0.000622	0.000622	CcSEcCtD
Darifenacin—Pruritus—Prednisone—systemic scleroderma	0.000615	0.000615	CcSEcCtD
Darifenacin—Feeling abnormal—Methotrexate—systemic scleroderma	0.000599	0.000599	CcSEcCtD
Darifenacin—Diarrhoea—Prednisone—systemic scleroderma	0.000595	0.000595	CcSEcCtD
Darifenacin—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000594	0.000594	CcSEcCtD
Darifenacin—Dizziness—Prednisone—systemic scleroderma	0.000575	0.000575	CcSEcCtD
Darifenacin—Abdominal pain—Methotrexate—systemic scleroderma	0.000575	0.000575	CcSEcCtD
Darifenacin—Vomiting—Prednisone—systemic scleroderma	0.000553	0.000553	CcSEcCtD
Darifenacin—Rash—Prednisone—systemic scleroderma	0.000548	0.000548	CcSEcCtD
Darifenacin—Dermatitis—Prednisone—systemic scleroderma	0.000548	0.000548	CcSEcCtD
Darifenacin—Headache—Prednisone—systemic scleroderma	0.000545	0.000545	CcSEcCtD
Darifenacin—Hypersensitivity—Methotrexate—systemic scleroderma	0.000536	0.000536	CcSEcCtD
Darifenacin—Asthenia—Methotrexate—systemic scleroderma	0.000522	0.000522	CcSEcCtD
Darifenacin—Nausea—Prednisone—systemic scleroderma	0.000517	0.000517	CcSEcCtD
Darifenacin—Pruritus—Methotrexate—systemic scleroderma	0.000514	0.000514	CcSEcCtD
Darifenacin—Diarrhoea—Methotrexate—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Darifenacin—Dizziness—Methotrexate—systemic scleroderma	0.000481	0.000481	CcSEcCtD
Darifenacin—Vomiting—Methotrexate—systemic scleroderma	0.000462	0.000462	CcSEcCtD
Darifenacin—Rash—Methotrexate—systemic scleroderma	0.000458	0.000458	CcSEcCtD
Darifenacin—Dermatitis—Methotrexate—systemic scleroderma	0.000458	0.000458	CcSEcCtD
Darifenacin—Headache—Methotrexate—systemic scleroderma	0.000455	0.000455	CcSEcCtD
Darifenacin—Nausea—Methotrexate—systemic scleroderma	0.000432	0.000432	CcSEcCtD
